Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Purchases 50,000 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan purchased 50,000 shares of the stock in a transaction dated Thursday, January 30th. The shares were bought at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the purchase, the chief executive officer now owns 260,808 shares in the company, valued at approximately $284,280.72. This trade represents a 23.72 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Regulus Therapeutics Stock Performance

NASDAQ:RGLS remained flat at $1.00 on Friday. 643,240 shares of the company’s stock were exchanged, compared to its average volume of 590,682. The stock has a market cap of $65.50 million, a P/E ratio of -0.93 and a beta of 1.60. The stock’s 50-day simple moving average is $1.47 and its two-hundred day simple moving average is $1.55. Regulus Therapeutics Inc. has a 52 week low of $0.83 and a 52 week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, analysts anticipate that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGLS. Creative Planning purchased a new position in shares of Regulus Therapeutics during the 3rd quarter worth about $26,000. SG Americas Securities LLC purchased a new position in shares of Regulus Therapeutics during the 3rd quarter worth about $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the 3rd quarter worth about $46,000. State Street Corp lifted its holdings in shares of Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after acquiring an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Regulus Therapeutics by 10.4% during the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after acquiring an additional 37,480 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.